Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
Kenney PA, Wood CG. Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. European Urology 2012, 62: 182-183. PMID: 22640859, DOI: 10.1016/j.eururo.2012.04.013.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaPhase 3 trialRenal cell carcinomaCell carcinomaComparative effectivenessCarcinomaSorafenibTrials